EP0679083A4 - Prävention und behandlung von sepsis. - Google Patents
Prävention und behandlung von sepsis.Info
- Publication number
- EP0679083A4 EP0679083A4 EP94909422A EP94909422A EP0679083A4 EP 0679083 A4 EP0679083 A4 EP 0679083A4 EP 94909422 A EP94909422 A EP 94909422A EP 94909422 A EP94909422 A EP 94909422A EP 0679083 A4 EP0679083 A4 EP 0679083A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- sepsis
- prevention
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
- C07K7/62—Polymyxins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
- C07K7/58—Bacitracins; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
- C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Insects & Arthropods (AREA)
- Toxicology (AREA)
- Zoology (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99538892A | 1992-12-21 | 1992-12-21 | |
US995388 | 1992-12-21 | ||
US16406793A | 1993-12-08 | 1993-12-08 | |
US164067 | 1993-12-08 | ||
US169701 | 1993-12-17 | ||
US08/169,701 US5545721A (en) | 1992-12-21 | 1993-12-17 | Conjugates for the prevention and treatment of sepsis |
PCT/US1993/012381 WO1994014437A1 (en) | 1992-12-21 | 1993-12-20 | Prevention and treatment of sepsis |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0679083A1 EP0679083A1 (de) | 1995-11-02 |
EP0679083A4 true EP0679083A4 (de) | 1999-03-24 |
Family
ID=27388964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94909422A Withdrawn EP0679083A4 (de) | 1992-12-21 | 1993-12-20 | Prävention und behandlung von sepsis. |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0679083A4 (de) |
JP (1) | JPH08504824A (de) |
AU (1) | AU693433B2 (de) |
CA (1) | CA2151386A1 (de) |
WO (1) | WO1994014437A1 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6579696B1 (en) * | 1992-12-21 | 2003-06-17 | Promega Corporation | Polymyxin B conjugates |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6086875A (en) * | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6030613A (en) * | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
WO2007038623A2 (en) * | 2005-09-28 | 2007-04-05 | Ventria Bioscience | Oral formulation for enteric disorders and/or rehydration |
WO2023080797A1 (en) * | 2021-11-05 | 2023-05-11 | Koru Diagnostics Limited | Method for detecting pathogenic gram-negative microorganisms and uses thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0088695A2 (de) * | 1982-03-09 | 1983-09-14 | Cytogen Corporation | Antikörper-Verbindungen |
EP0122132A2 (de) * | 1983-04-08 | 1984-10-17 | Kureha Kagaku Kogyo Kabushiki Kaisha | Antikrebsmittel |
WO1989004672A1 (en) * | 1987-11-20 | 1989-06-01 | The Upjohn Company | Derivatives of lincosaminide antibiotics |
WO1990003401A1 (en) * | 1988-09-30 | 1990-04-05 | Neorx Corporation | Targeting substance-diagnostic/therapeutic agent conjugates having schiff base linkages |
WO1992020715A1 (en) * | 1991-05-16 | 1992-11-26 | Associates Of Cape Cod, Inc. | Endotoxin binding and neutralizing protein and uses thereof |
WO1995005393A2 (en) * | 1993-08-18 | 1995-02-23 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Lipopolysaccharide-binding and neutralizing peptides |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4067776A (en) * | 1975-11-25 | 1978-01-10 | Research Foundation Of Children's Hospital | Method for differential diagnosis of meningitis with a limulus lysate test |
US4867973A (en) * | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
US4666884A (en) * | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
US4918163A (en) * | 1985-09-27 | 1990-04-17 | Pfizer Inc. | Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria |
AU639952B2 (en) * | 1989-11-15 | 1993-08-12 | Novartis Ag | Polymyxin conjugates |
-
1993
- 1993-12-20 JP JP6515349A patent/JPH08504824A/ja active Pending
- 1993-12-20 AU AU62269/94A patent/AU693433B2/en not_active Ceased
- 1993-12-20 EP EP94909422A patent/EP0679083A4/de not_active Withdrawn
- 1993-12-20 CA CA002151386A patent/CA2151386A1/en not_active Abandoned
- 1993-12-20 WO PCT/US1993/012381 patent/WO1994014437A1/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0088695A2 (de) * | 1982-03-09 | 1983-09-14 | Cytogen Corporation | Antikörper-Verbindungen |
EP0122132A2 (de) * | 1983-04-08 | 1984-10-17 | Kureha Kagaku Kogyo Kabushiki Kaisha | Antikrebsmittel |
WO1989004672A1 (en) * | 1987-11-20 | 1989-06-01 | The Upjohn Company | Derivatives of lincosaminide antibiotics |
WO1990003401A1 (en) * | 1988-09-30 | 1990-04-05 | Neorx Corporation | Targeting substance-diagnostic/therapeutic agent conjugates having schiff base linkages |
WO1992020715A1 (en) * | 1991-05-16 | 1992-11-26 | Associates Of Cape Cod, Inc. | Endotoxin binding and neutralizing protein and uses thereof |
WO1995005393A2 (en) * | 1993-08-18 | 1995-02-23 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Lipopolysaccharide-binding and neutralizing peptides |
Non-Patent Citations (5)
Title |
---|
ALPERT G. ET AL: "Limulus antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock", JOURNAL OF INFECTIOUS DISEASES, vol. 165, 1992, pages 494 - 500, XP002085408 * |
BOORSMA D. M. ET AL: "Periodate or glutaraldehyde for preparing peroxidase conjugates?", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 30, 1979, pages 245 - 255, XP002085409 * |
DRABICK JJ ET AL: "Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin reagent.", ANTIMICROB AGENTS CHEMOTHER, MAR 1998, 42 (3) P583-8, UNITED STATES, XP002073819 * |
FISCHER G.W.: "Use of intravenous immune globulin in newborn infants", CLIN. EXP. IMMUNOL. SUPPL., 1994, 97/1 (73-77), United Kingdom, XP002073910 * |
See also references of WO9414437A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU6226994A (en) | 1994-07-19 |
WO1994014437A1 (en) | 1994-07-07 |
EP0679083A1 (de) | 1995-11-02 |
AU693433B2 (en) | 1998-07-02 |
CA2151386A1 (en) | 1994-07-07 |
JPH08504824A (ja) | 1996-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA945426B (en) | Treatment of tachyarrhytmias of supraventricular origin | |
ZA933519B (en) | Treatment of wastewater | |
ZA931714B (en) | Combination of ace inhibitors and diuretics. | |
EP0584340A4 (en) | Diagnosis and treatment of various neuralgias | |
AU6946594A (en) | Methods for the treatment and prevention of diarrhea | |
AU6160594A (en) | Diabetes prevention and treatment | |
ZA935575B (en) | Therapeutic agent and its use. | |
EP0708738A4 (de) | Behandlung von fluiden | |
GB9203039D0 (en) | Treatment | |
GB2271579B (en) | Treatment of wood | |
EP0679083A4 (de) | Prävention und behandlung von sepsis. | |
GB9211736D0 (en) | Allergic treatment | |
IL104472A0 (en) | Substituted hexahydro-azepinones and tetrahydro-benzazepinones | |
EP0644221A3 (de) | Herstellung und Verarbeitung von Polydiorganosiloxanen. | |
GB9317943D0 (en) | Treatment of laminitis | |
ZA93348B (en) | Treatment of liquids. | |
ZA93491B (en) | Treatment of psychoses | |
ZA932458B (en) | Naphtoquinones and their use. | |
GB9412413D0 (en) | Boiler treatment and novel compounds therefor | |
GB9408916D0 (en) | Treatment of sewage | |
GB9317989D0 (en) | Treatment of laminitis | |
GB9321591D0 (en) | Novel compounds and treatment | |
GB9302314D0 (en) | Novel compounds and treatment | |
GB9302289D0 (en) | Novel compounds and treatment | |
GB9321592D0 (en) | Novel compounds and treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19950720 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19990206 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20000315 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PROMEGA CORPORATION |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20020701 |